Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05697809 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
A Phase 2 study, sponsored by Oxular Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05697809: Completed Phase 2 study, sponsored by Oxular Limited.
NCT05697809 is a Phase 2 study that has completed, run by Oxular Limited. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05697809, a Phase 2 study, has completed, sponsored by Oxular Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device compared with intravitreal dexamethasone implant (OZURDEX®) in subjects with diabetic macular edema.
Primary Outcome
Treatment-emergent adverse events are defined as events emerging following administration of study treatment (OXU-001 administered with the Oxulumis suprachoroidal administration device) at Visit 2 (Baseline, Day 0)
Interventions
- DRUG OXU-001
- DEVICE Semi-automated suprachoroidal illuminated microcatheter
- DRUG Ozurdex® Ophthalmic Intravitreal Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 2 |
What the finished NCT05697809 record still lists
NCT05697809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which OXU-001 is the first listed.
NCT05697809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05697809 about?
NCT05697809 is a clinical study titled "Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema". The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device compared with intravitreal dexamethaso...
What is the current status of trial NCT05697809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2023-08-07. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT05697809?
The interventions under investigation include: OXU-001 (DRUG), Semi-automated suprachoroidal illuminated microcatheter (DEVICE), Ozurdex® Ophthalmic Intravitreal Implant (DRUG).
Who is sponsoring clinical trial NCT05697809?
This trial is sponsored by Oxular Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05697809's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI